Overview

Zanubrutinib for HLH

Status:
Recruiting

Trial end date:
2023-04-01

Target enrollment:

Participant gender:

Summary

This study is a prospective single-arm clinical study, focusing on Hemophagocytic lymphohistocytosis，to evaluate the clinical efficacy and safety of zanubrutinib.

Phase:

Phase 3

Details

Lead Sponsor:

Beijing Friendship Hospital

Treatments:

Zanubrutinib